Shirmohammadi Zeshkian F, Srinivasan R
Department of Pharmacy Practice, P.E.S. College of Pharmacy, Rajiv Gandhi University of Health Sciences, Bangalore, India.
Arch Razi Inst. 2024 Jun 30;79(3):617-622. doi: 10.32592/ARI.2024.79.3.617. eCollection 2024 Jun.
Hepatic encephalopathy (HE) is a clinical syndrome that can result from acute and chronic liver disorders, such as hepatitis, liver failure caused by alcohol or drugs, autoimmune diseases, metabolic diseases, cirrhosis, different types of tumors, and infections. This study aimed to investigate the effects of different doses of Beta-myrcene (β-myrcene) on the improvement of HE caused by thioacetamide (TAC) in male rats. To induce liver failure and acute damage in the studied animals, TAC was administered to rats at a dose of 100 mg/kg of body weight through an intraperitoneal (IP) injection with 24-hour intervals for seven consecutive days. After the oral treatment of rats with β-myrcene at doses of 10, 25, and 50 mg/kg/day for seven days, the cerebral edema (brain water content, BWC), the serum level of liver enzymes (aspartate aminotransferase, alanine transferase, alkaline transferase, total protein, and bilirubin), ammonia, and the level of oxidant-antioxidant factors (lipid peroxidation [MDA], glutathione peroxidase [GPx], catalase [CAT], and superoxide dismutase enzymes [SOD]), were evaluated. β-myrcene dose-dependently reduced BWC in TAC-induced acute HE in rats. In TAC rats treated with β-myrcene, especially at doses of 25 and 50 mg/kg, the serum levels of these liver enzymes and ammonia were significantly moderated (<0.001), compared to the untreated TAC rats. The analysis of the obtained results revealed that the treatment of TAC rats with β-myrcene, especially at doses of 25 and 50 mg/kg, significantly reduced the oxidative stress marker MDA (<0.001), whereas it significantly increased the antioxidant enzymes SOD, CAT, and GPx (<0.001). Therefore, it can be concluded that the treatment of TAC rats with β-myrcene, especially at doses of 25 and 50 mg/kg, significantly reduced the oxidative stress marker MDA, whereas it significantly increased antioxidant enzymes and subsequently improved TAC-induced acute HE in rats.
肝性脑病(HE)是一种临床综合征,可由急性和慢性肝脏疾病引起,如肝炎、酒精或药物所致肝衰竭、自身免疫性疾病、代谢性疾病、肝硬化、不同类型的肿瘤及感染。本研究旨在探讨不同剂量的β-月桂烯(β-myrcene)对改善硫代乙酰胺(TAC)所致雄性大鼠肝性脑病的作用。为在研究动物中诱导肝衰竭和急性损伤,以100 mg/kg体重的剂量通过腹腔内(IP)注射,每隔24小时给大鼠注射一次TAC,连续注射7天。在以10、25和50 mg/kg/天的剂量给大鼠口服β-月桂烯7天后,评估脑水肿(脑含水量,BWC)、肝酶(天冬氨酸转氨酶、丙氨酸转氨酶、碱性磷酸酶、总蛋白和胆红素)血清水平、氨以及氧化-抗氧化因子水平(脂质过氧化[MDA]、谷胱甘肽过氧化物酶[GPx]、过氧化氢酶[CAT]和超氧化物歧化酶[SOD])。β-月桂烯剂量依赖性地降低了TAC诱导的大鼠急性肝性脑病中的BWC。在用β-月桂烯治疗的TAC大鼠中,尤其是25和50 mg/kg剂量组,与未治疗的TAC大鼠相比,这些肝酶和氨的血清水平显著降低(<0.001)。对所得结果的分析表明,用β-月桂烯治疗TAC大鼠,尤其是25和50 mg/kg剂量组,显著降低了氧化应激标志物MDA(<0.001),而显著增加了抗氧化酶SOD、CAT和GPx(<0.001)。因此,可以得出结论,用β-月桂烯治疗TAC大鼠,尤其是25和50 mg/kg剂量组,显著降低了氧化应激标志物MDA,而显著增加了抗氧化酶,随后改善了TAC诱导的大鼠急性肝性脑病。